TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe

Cancer Letters

Volumn 293, Issue 1, 2010, Pages 92-98

  Szymanska K ^a   Moore, L E ^b   Rothman, N ^b   Chow, W H ^b   Waldman, F ^c   Jaeger, E ^c   Waterboer, T ^d   Foretova, L ^e   Navratilova, M ^e   Janout, V ^f   Kollarova, H ^f   Zaridze, D ^g   Matveev, V ^g   Mates, D ^h   Szeszenia Dabrowska, N ⁱ   Holcatova, I ^j   Bencko, V ^j   Le Calvez Kelm, F ^a   Villar, S ^a   Pawlita, M ^d   Boffetta, P ^a   Hainaut, P ^a   Brennan, P ^a   more..

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^f PALACKÝ UNIVERSITY   (Czech Republic)

^g N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^h NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

ⁱ NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^j NONE

more..

Author keywords

Cancer; EGFR; Renal carcinoma; TP53 mutations; VHL

Indexed keywords

K RAS PROTEIN; PROTEIN P53; VON HIPPEL LINDAU PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; EASTERN EUROPE; FEMALE; GENE FUNCTION; GENE INACTIVATION; GENE INTERACTION; GENE MUTATION; HIGH RISK BEHAVIOR; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CASE-CONTROL STUDIES; EUROPE; FEMALE; GENE SILENCING; GENES, ERBB-1; GENES, P53; GENES, RAS; HUMANS; KIDNEY NEOPLASMS; LIFE STYLE; MALE; MIDDLE AGED; MUTATION; RISK FACTORS; TUMOR CELLS, CULTURED;

EID: 77952545672     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.11.024     Document Type: Article

References (19)

1. J. Ferlay, F.I. Bray, P. Pisani, D.M. Parkin, Globocan, Ref Type: Data File, 2002.
2. Hunt J.D., van der Hel O.L., McMillan G.P., Boffetta P., Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int. J. Cancer 2005, 114:101-108.
3. Pan S.Y., DesMeules M., Morrison H., Wen S.W. Obesity, high energy intake, lack of physical activity, and the risk of kidney cancer. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2453-2460.
4. Reeves G.K., Pirie K., Beral V., Green J., Spencer E., Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007, 335:1134.
5. Weikert S., Boeing H., Pischon T., Weikert C., Olsen A., Tjonneland A., Overvad K., Becker N., Linseisen J., Trichopoulou A., Mountokalakis T., Trichopoulos D., Sieri S., Palli D., Vineis P., Panico S., Peeters P.H., Bueno-de-Mesquita H.B., Verschuren W.M., Ljungberg B., Hallmans G., Berglund G., Gonzalez C.A., Dorronsoro M., Barricarte A., Tormo M.J., Allen N., Roddam A., Bingham S., Khaw K.T., Rinaldi S., Ferrari P., Norat T., Riboli E. Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am. J. Epidemiol. 2007.
6. Gnarra J.R., Tory K., Weng Y., Schmidt L., Wei M.H., Li H., Latif F., Liu S., Chen F., Duh F.M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat. Genet. 1994, 7:85-90.
7. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 2007, 28:622-629.
8. Haitel A., Wiener H.G., Baethge U., Marberger M., Susani M. mdm2 expression as a prognostic indicator in clear cell renal cell carcinoma: comparison with p53 overexpression and clinicopathological parameters. Clin. Cancer Res. 2000, 6:1840-1844.
9. Ljungberg B., Bozoky B., Kovacs G., Stattin P., Farrelly E., Nylander K., Landberg G. p53 expression in correlation to clinical outcome in patients with renal cell carcinoma. Scand. J. Urol. Nephrol. 2001, 35:15-20.
10. Galban S., Martindale J.L., Mazan-Mamczarz K., Lopez de Silanes I., Fan J., Wang W., Decker J., Gorospe M. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells. Mol. Cell Biol. 2003, 23:7083-7095.
11. Stickle N.H., Cheng L.S., Watson I.R., Alon N., Malkin D., Irwin M.S., Ohh M. Expression of p53 in renal carcinoma cells is independent of pVHL. Mutat. Res. 2005, 578:23-32.
12. Dreijerink K., Braga E., Kuzmin I., Geil L., Duh F.M., Angeloni D., Zbar B., Lerman M.I., Stanbridge E.J., Minna J.D., Protopopov A., Li J., Kashuba V., Klein G., Zabarovsky E.R. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc. Natl. Acad. Sci. USA 2001, 98:7504-7509.
13. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., Varmus H. EGF receptor gene mutations are common in lung cancers from " never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 2004, 101:13306-13311.
14. Sakaeda T., Okamura N., Gotoh A., Shirakawa T., Terao S., Morioka M., Tokui K., Tanaka H., Nakamura T., Yagi M., Nishimura Y., Yokoyama M., Okumura K. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm. Res. 2005, 22:1757-1761.
15. Le Calvez F., Ahman A., Tonisson N., Lambert J., Temam S., Brennan P., Zaridze D.G., Metspalu A., Hainaut P. Arrayed primer extension resequencing of mutations in the TP53 tumor suppressor gene: comparison with denaturing HPLC and direct sequencing. Clin. Chem. 2005, 51:1284-1287.
16. M. Nickerson, E. Jaeger, J. Durocher, K. Walters, Y. Shi, M. Smithhisler, D. Zaridze, V. Janout, H. Kollarova, V. Bencko, M. Navratilova, N. Szeszenia-Dabrowska, D. Mates, A. Mukeria, I. Holcatova, L. Schmidt, J. Toro, S. Karami, R. Hung, G. Gerard, W. Linehanl, M. Merino, B. Zbar, P. Boffetta, Brennan P, N. Rothman, W.H. Chow, F. Waldman, L. Moore, Improved identification of Von Hippel-Lindau gene alterations in clear cell renal tumors, Clin. Cancer Res., 14 (2008) 4726-4734.
17. Waterboer T., Sehr P., Michael K.M., Franceschi S., Nieland J.D., Joos T.O., Templin M.F., Pawlita M. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin. Chem. 2005, 51:1845-1853.
18. Contractor H., Zariwala M., Bugert P., Zeisler J., Kovacs G. Mutation of the p53 tumour suppressor gene occurs preferentially in the chromophobe type of renal cell tumour. J. Pathol. 1997, 181:136-139.
19. Gad S., Lefevre S.H., Khoo S.K., Giraud S., Vieillefond A., Vasiliu V., Ferlicot S., Molinie V., Denoux Y., Thiounn N., Chretien Y., Mejean A., Zerbib M., Benoit G., Herve J.M., Allegre G., Bressac-de P.B., Teh B.T., Richard S. Mutations in BHD and TP53 genes but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Brit. J. Cancer 2007, 96:336-340.